Glyscend Therapeutics' early data show polymer mimics benefits of surgery in type 2 diabetes, obesity
Glyscend Therapeutics released topline data for its polymer targeting type 2 diabetes and obesity today, with the hopes the candidate will have the same effects …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.